The RK-1 continuous mixing processor from Readco Kurimoto is suited for testing formulations in continuous processing conditions.
Courtesy Readco
Process equipment manufacturer Readco Kurimoto introduced the RK-1 continuous mixing processor, which incorporates the company's proprietary mixing technology in a compact, tabletop unit. The company states that the unit was developed to help product development professionals test new and existing formulations being processed in batches using a continuous process in a controlled, laboratory environment. Scaled down to process 10 lbs/hr, the RK-1 combines heat transfer, mixing, and shear to process multiple powdered, liquid, and viscous ingredients in a single step, while yielding a high quality, homogeneous product at discharge that meets targeted specifications for moisture, texture, color, uniformity, and other criteria.
The novel RK-1 features twin shaft, co-rotating screws with a one-inch diameter set within a closed barrel to promote the intimate contact among wet and dry materials needed to achieve the desired level of mixing, blending, reacting, crystallization, and/or encapsulation. Suitable for use in research and development laboratories for pharmaceuticals and other products, the versatile RK-1 includes touch-screen controls for setup, monitoring, and real-time adjustments. Other available options include a mobile lift table, electric band heater, feed chute, and all-stainless steel construction.
The RK-1 continuous processors are engineered and manufactured in the company's York, PA headquarters. The lab-size processors operate on 220 volts single-phase and are delivered ready to plug in and operate.
Source: Readco
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.